HMGB2 与 HMGB1 的差异特征及其在卵巢癌和前列腺癌中的研究进展。

Differential Characteristics of HMGB2 Versus HMGB1 and their Perspectives in Ovary and Prostate Cancer.

机构信息

EXPRELA Group, Centro de Investigacions Cientificas Avanzadas (CICA), Departamento de Bioloxia. Facultade de Ciencias, INIBIC- Universidade da Coruna, Campus de A Zapateira, 15071, A Coruna, Spain.

Translational Cancer Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Carretera del Pasaje s/n, 15006 A Coruña, Spain.

出版信息

Curr Med Chem. 2020;27(20):3271-3289. doi: 10.2174/0929867326666190123120338.

DOI:10.2174/0929867326666190123120338

PMID:30674244

Abstract

We have summarized common and differential functions of HMGB1 and HMGB2 proteins with reference to pathological processes, with a special focus on cancer. Currently, several "omic" approaches help us compare the relative expression of these 2 proteins in healthy and cancerous human specimens, as well as in a wide range of cancer-derived cell lines, or in fetal versus adult cells. Molecules that interfere with HMGB1 functions, though through different mechanisms, have been extensively tested as therapeutic agents in animal models in recent years, and their effects are summarized. The review concludes with a discussion on the perspectives of HMGB molecules as targets in prostate and ovarian cancers.

摘要

我们总结了 HMGB1 和 HMGB2 蛋白在病理过程中的常见和差异功能，特别关注癌症。目前，几种“组学”方法帮助我们比较这两种蛋白质在健康和癌症人类标本中的相对表达，以及在广泛的癌症衍生细胞系中，或在胎儿与成人细胞中的相对表达。近年来，通过不同机制干扰 HMGB1 功能的分子已在动物模型中作为治疗剂进行了广泛测试，并总结了它们的作用。本文最后讨论了 HMGB 分子作为前列腺癌和卵巢癌靶点的前景。